<DOC>
	<DOCNO>NCT02191761</DOCNO>
	<brief_summary>This open-label , multi-center , dose escalation study adult subject advance colorectal , gastric , hepatic pancreatic cancer . The study evaluate safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) SM04755 administer orally . Upon determination maximum tolerate dose ( MTD ) , expansion cohort may enrol .</brief_summary>
	<brief_title>Safety Pharmacokinetics SM04755 Subjects With Advanced Colorectal , Gastric , Hepatic , Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Subjects advance colorectal , gastric , hepatic pancreatic cancer Subjects must recover toxicity associate previous chemotherapy , target therapy , radiotherapy Subjects must meet certain laboratory criterion Expected survival &gt; 3months Subjects must uncontrolled intercurrent illness Women pregnant lactating , childbearing potential , men use barrier method Subjects significant cardiac issue Subjects use certain medication Subjects certain medical condition Subjects brain metastasis Subjects recently enrol experimental clinical trial investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>